Testosterone cypionate

Generic Name: Testosterone cypionate

Brand Names: Depo-testosterone

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 58-20-8

Unique Ingredient Identifier: M0XW1UBI14

Background: Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

Indication: Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism

Clinical Trials

The COSMYC Trial (COmbined Suppression of MYC)

Phase 2

Not yet recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: ZEN-3694
Drug: Testosterone cypionate
Drug: Enzalutamide
Drug: Luteinizing hormone-releasing hormone (LHRH) analogue

First Posted Date: 2025-04-10

Last Posted Date: 2025-04-10

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 50

Registration Number: NCT06922318

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Leuprolide Acetate
Procedure: Magnetic Resonance Imaging
Other: Survey Administration
Drug: Testosterone Cypionate

First Posted Date: 2024-03-12

Last Posted Date: 2025-01-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 14

Registration Number: NCT06305598

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

Phase 2

Recruiting

Conditions: Stress Urinary Incontinence
Menopause

Interventions: Drug: Testosterone cypionate
Drug: Placebo

First Posted Date: 2023-11-01

Last Posted Date: 2025-05-14

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 30

Registration Number: NCT06111209

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC

Phase 2

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Testosterone Cypionate
Drug: Sipuleucel-T

First Posted Date: 2023-10-25

Last Posted Date: 2024-11-05

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT06100705

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: DFMO
Drug: testosterone cypionate
Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
Drug: Enzalutamide

First Posted Date: 2023-09-28

Last Posted Date: 2025-02-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 50

Registration Number: NCT06059118

Locations: 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Phase 2

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Testosterone Cypionate

First Posted Date: 2023-09-15

Last Posted Date: 2024-09-30

Lead Sponsor: University of Washington

Target Recruit Count: 46

Registration Number: NCT06039371

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

Phase 2

Recruiting

Conditions: Pain
Androgen Deficiency
Opioid Use
Back Pain

Interventions: Drug: Placebo
Drug: Testosterone Cypionate

First Posted Date: 2021-05-20

Last Posted Date: 2025-05-07

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 40

Registration Number: NCT04895306

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Danazol
Drug: Bupropion
Drug: Anastrozole
Drug: Chlorthalidone
Drug: Testosterone cyclopentylpropionate

First Posted Date: 2021-02-17

Last Posted Date: 2021-04-26

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 9

Registration Number: NCT04757532

Locations: 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Phase 1

Recruiting

Conditions: Malignant Urinary System Neoplasm
Hypogonadism
Urinary System Disorder
Urinary System Neoplasm

Interventions: Other: Best Practice
Procedure: Quality-of-Life Assessment
Drug: Testosterone Cypionate
Other: Questionnaire Administration

First Posted Date: 2021-02-01

Last Posted Date: 2024-12-27

Lead Sponsor: Emory University

Target Recruit Count: 100

Registration Number: NCT04731376

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Testosterone Cypionate
Drug: Darolutamide

First Posted Date: 2020-09-22

Last Posted Date: 2024-04-02

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 51

Registration Number: NCT04558866

Locations: 🇧🇷
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio De Janeiro, Brazil
🇧🇷
HMV - Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Sírio-Libanês SP, São Paulo, Brazil

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy